Rasio rega marang prakiraan pendapatan Mustang Bio Inc (MBIO)
Mustang Bio, Inc. (MBIO) is optimizing capital through university partnerships in the development of CAR-T therapies. The projected P/S ratio visualizes market expectations, where reflects the current value of the metric. A team of top biologists is advancing genetic engineering, driven by strong financial incentives. Proprietary patents and stringent FDA requirements create an insurmountable barrier to entry for new players in the sector.
Mustang Bio - rincian analitis lan metrik utama (MBIO)
- rega saiki lan proyeksi nilai saham:
- rincian kapitalisasi pasar:
- indikator nilai buku ekuitas:
- data utang lan likuiditas:
Utang marang Ekuitas Mustang Bio, Inc.|MBIO - Rasio utang jangka dawa marang modal|Utang jangka cendhak marang modal Mustang Bio, Inc.|MBIO - Gunggung utang perusahaan|Utang marang nilai buku Mustang Bio Corp|MBIO - Gunggunge utang jangka dawa|Utang jangka cendhak perusahaan Mustang Bio|Rasio cepet mustangbio.com
- indikator pendapatan resik lan kelipatan nilai:
MBIO - Bathi resik perusahaan|Proyeksi bathi mangsa ngarep Mustang Bio, Inc.|MBIO - Periode bali modal bisnis|Rega marang bathi mangsa ngarep Mustang Bio|MBIO - Rega marang bathi kanthi panyesuaian wutah|Pangali EV/EBITDA Mustang Bio Corp|MBIO - Bathi operasional sadurunge amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Mustang Bio|MBIO - Bathi saben saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan mustangbio.com|MBIO - Wutah bathi ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Mustang Bio, Inc.
- statistik dodolan lan pendapatan perusahaan:
Analisis kabeh metrik perusahaan:Mustang Bio Inc (MBIO)
For Mustang Bio, Inc. (MBIO), which develops radical CAR-T therapies for oncology, valuation is based on expectations of future commercial success. By analyzing forward P/S changes on GURU.Markets, an investor can view the ratio of current market capitalization to projected revenue, making it possible to determine the asset's degree of overheating relative to industry trends and avoid the risks of unjustifiably inflated multiples when buying.
Analisis perusahaan pesaing
Multiplikator Forward P/S TEM (Tempus Labs)|Qiagen N.V. - Rasio rega marang prakiraan pendapatan|IONS - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep repligen.com|RNA: Multiplikator Forward P/S|CRISPR Therapeutics Inc (CRSP) - Multiplikator Forward P/S|WGS (GeneDx Holdings) - Multiplikator Forward P/S|RARE: Rega forward marang dodolan|Multiplikator forward rega marang pendapatan BEAM (Beam Therapeutics Corp)|SRPT: Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S TWST (Twist Bioscience Inc)|Rasio kapitalisasi marang dodolan sing dikarepake 10x Genomics Corp (TXG)|intelliatx.com - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake Stoke STOK|biolifesolutions.com (BLFS) - Rasio rega marang prakiraan pendapatan|WVE - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan MAZE|Multiplikator forward rega marang pendapatan Sionna Therapeutics, Inc. (SION)|Multiplikator forward rega marang pendapatan PRME (Prime Medicine Bio)|Rasio kapitalisasi marang dodolan sing dikarepake Taysha|uniQure Pharma - Multiplikator forward rega marang pendapatan|MeiraGTx Holdings plc - Rasio rega marang prakiraan pendapatan|regenxbio.com - Multiplikator Forward P/S|Solid Bio (SLDB) - Multiplikator forward rega marang pendapatan|OCGN: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Pacific Biosciences of California|BNTC (Benitec Biopharma Inc.) - Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan DSGN (Design Therapeutics)|Multiplikator Forward P/S RCKT|Rasio rega marang prakiraan pendapatan FDMT (4D Molecular Therapeutics Inc)|Multiplikator Forward P/S LXEO (Lexeo Therapeutics Inc.)|Rega forward marang dodolan KRRO|EDIT - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Silence Therapeutics SLN|ProQR Therapeutics NV (PRQR) - Rasio rega marang prakiraan pendapatan|Codexis Inc - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Sangamo BioSciences|Kapitalisasi marang prakiraan pendapatan NAUT (Nautilus Biotechnology)|Rasio rega marang prakiraan pendapatan metagenomi.co (MGX)|DTIL: Rega mangsa ngarep marang pendapatan|Rasio rega marang prakiraan pendapatan Generation Bio Co. GBIO|BOLD: Kapitalisasi marang prakiraan pendapatan|XCUR: Multiplikator forward rega marang pendapatan|Imunon (IMNN) - Multiplikator forward rega marang pendapatan|PHIO (RXi Pharmaceuticals) - Multiplikator forward rega marang pendapatan|TransCode (RNAZ) - Multiplikator Forward P/S|BNGO (Bionano) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Applied DNA Sciences, Inc. APDN|Multiplikator Forward P/S BLUE|ImmunoPrecise Antibodies Ltd - Kapitalisasi marang prakiraan pendapatan|Rasio rega marang prakiraan pendapatan Omega Therapeutics OMGA|OMIC: Kapitalisasi marang prakiraan pendapatan|RGLS: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan SYRS (Syros Pharmaceuticals, Inc.)|Telesis Bio, Inc. (TBIO) - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan TCON (TRACON)|Rasio rega marang prakiraan pendapatan Unity Biotechnology, Inc.
